Role of alternative oral therapy for the management of wet age-related macular degeneration and proliferative diabetic retinopathy

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

565

Tables (1-1)

Sum=619

Publishing Process of This Article

Item

Count

Browse

Download

Sum=30

Aug 15, 2025 (publication date) through Aug 23, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Diabetes. Aug 15, 2025; 16(8): 109231
Published online Aug 15, 2025. doi: 10.4239/wjd.v16.i8.109231

Table 1 Molecular structure of fenofibrate, candesartan, and vorolanib

Name of oral drug	Molecular structure
Fenofibrate	C₂₀H₂₁CIO₄, with a molecular weight of 360.8 g/mol
Candesartan	C₂₄H₂₀N₆O₃, with a molecular weight of 440.46 g/mol
Vorolanib	C₂₃H₂₆FN₅O₃, with a molecular weight of 439.49 g/mol

Citation: Walia S, Morya AK, Khullar S, Aggarwal S, Kaur R. Role of alternative oral therapy for the management of wet age-related macular degeneration and proliferative diabetic retinopathy. World J Diabetes 2025; 16(8): 109231
URL: https://www.wjgnet.com/1948-9358/full/v16/i8/109231.htm
DOI: https://dx.doi.org/10.4239/wjd.v16.i8.109231